Kalbe Farma's (KLBF) Strategy to Maintain Strong Performance in 2025

Kalbe Farma's (KLBF) Strategy to Maintain Strong Performance in 2025

Kalbe Farma (KLBF) continues to strengthen its revenue from the prescription drug segment to sustain the positive performance achieved through Q1 2025.

user-profile

Sabtu, 24 Mei 2025 | 19:21

Bisnis.com, JAKARTA — Pharmaceutical issuer PT Kalbe Farma Tbk. (KLBF) continues to drive revenue growth in the prescription drug segment to sustain the positive performance achieved through Q1/2025. The company has also initiated expansion efforts to support this goal.

Director Kartika Setiabudy stated that KLBF is closely monitoring the utilization rate of its current capacity and remains committed to expanding, particularly in the rapidly growing prescription drug segment.

Bacaanmu terbatas?

Tenang, kamu hanya perlu Masuk atau Daftar dulu di sini untuk lanjut membaca Bisnis Indonesia Premium.

Nikmati Gratis Akses baca 5 artikel Bisnis Indonesia Premium bagi member baru!

atau langsung pilih paket terbaik kami:

banner-promo

faq

berita lainnya

To Top